StockData
CGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

COMPUGEN LTD

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 2, 2026
$1.97+0.01 (+0.51%)

Close on Oct 19, 2026

Market cap
–
P/E (TTM)
5.2
Dividend yield
–

COMPUGEN LTD revenue by segment

No segment breakdown reported

Compugen does not break out revenue by segment, region or product in the tagged data of its filings for this period type.